Adaptive Biotechnologies (ADPT) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 5, 2026, to be held virtually for shareholder convenience.

• Shareholders of record as of April 7, 2026, are eligible to vote on key proposals.

Voting matters and shareholder proposals

• Election of two Class I director nominees, Robert Hershberg and Katey Owen, for three-year terms expiring in 2029.

• Advisory vote to approve executive compensation as outlined in the proxy statement.

• Ratification of Ernst & Young LLP as independent auditor for the fiscal year ending December 31, 2026.

• Provision to address any other business properly brought before the meeting.

Board of directors and corporate governance

• Board recommends voting in favor of all three main proposals.

• Director nominees have advanced degrees and relevant expertise.